Perspectives on clinical supply chain strategy, risk, forecasting, and operational excellence.
The last shipment out of a depot is the easy part. The hard part — the one inspectors will spend hours on — is proving you can account for every kit of investigational product that ever left the manufacturer. From first patient in to destruction certificate, the chain of custody has to close cleanly, or a good trial finishes with a warning letter.
Your IRT system will randomize patients, assign kits, protect the blind, and trigger every resupply shipment for the life of the trial. It is, functionally, the brain of your clinical supply chain.
If you're a sponsor moving toward commercial launch, or you're operating anywhere in the US prescription drug distribution chain, here's what actually applies now and what the last deadline means.
In a global trial, you don't run your own supply chain. You run a network of other people's — a CMO here, a packaging vendor there, a central depot, three regional depots, a courier network, and sixty sites. Your drug spends almost its entire life in someone else's building or someone else's truck.
Roughly two-thirds of clinical trials rely on a comparator or co-therapy — and sourcing it is one of the most underestimated parts of the whole supply chain. In one industry survey, around three-quarters of respondents said they'd hit a challenge sourcing comparators or ancillaries. And the money is far from trivial: by some long-standing estimates, sponsors spend on the order of $50 million on clinical supplies for a program, with roughly half of that going to comparators.
If you've spent any time in clinical supply, you know the artifact: a spreadsheet with forty rows, each scored on a probability-times-impact scale, color-coded red-amber-green, built during study start-up, presented once at a kickoff meeting, and then quietly abandoned.
The biopharma industry loses an estimated $35 billion a year to failures in temperature-controlled logistics — lost product, replacement costs, wasted shipping, and the root-cause work that follows. For a clinical trial, the math is even more painful, because the product that just sat on a hot tarmac for six hours isn't a commercial SKU you can remanufacture next week. It's irreplaceable investigational material tied to a specific patient on a specific visit date.
There are two ways a clinical supply chain can embarrass you. The first is a stockout — a patient arrives for a visit and the drug isn't there. The second is the quieter, more expensive one: at the end of the trial you destroy a warehouse full of unused, expired product. Both come from the same root cause. Both are forecasting failures.
A clinical trial can take 10 to 15 years and frequently costs well over a billion dollars to bring a single drug to market — and only about one in eight molecules that enter clinical testing ever reaches approval.
Cold chain failures don’t just cost money — they destroy product, delay treatment, and erode trust. Biologics and cell/gene therapies demand a level of temperature control that legacy cold chain systems were never designed to handle. The next generation of cold chain — Cold Chain 2.0 — integrates real‑time monitoring, redundancy, predictive analytics, and digital […]
What if the biggest cost driver in your clinical supply chain isn’t API, packaging, or logistics—but the quality of your decisions? In clinical supply, we obsess over precision: forecasts, expiry dating, depot capacity, comparator sourcing, packaging runs, IVR thresholds. Yet the real leverage point is often upstream—how teams think, structure information, and make decisions under […]
What if the biggest difference between average clinical supply leaders and great ones isn’t resources, headcount, or technology — but the patterns in how they think and operate? Across companies, therapeutic areas, and organizational maturities, I keep seeing the same behaviors separate the truly exceptional from the merely functional. Three patterns stand out: 1. They […]
What if the “urgent” issues consuming your team aren’t actually emergencies—just symptoms of a system you haven’t redesigned yet? In clinical supply chain, fire drills don’t just burn time. They burn credibility, budget, and study timelines. After 25+ years in this space, I see the same three patterns repeat across sponsors, CROs, and […]
Strategy Reshoring isn’t a trend — it’s a structural shift that will redefine pharma operations for the next decade. Tariffs, geopolitical instability, and FDA policy shifts are accelerating the move toward domestic manufacturing. But the impact goes far beyond facility location. It reshapes sourcing strategies, capacity planning, cost structures, and risk models across the entire […]
When was the last time your supply chain told you something you didn’t already know? After almost three decades leading global operations and clinical supply teams, I’ve learned this: Surprises rarely come from complexity — they come from leaders not asking the right questions often enough. A disciplined weekly cadence is one of […]
What if the greatest test of leadership isn’t how well you perform in moments of clarity—but how you show up when the path forward is anything but clear? After 25 years leading global operations across the pharmaceutical value chain, that question has shaped more of my career than any KPI, system upgrade, or organizational redesign. […]
What if the biggest financial leak in your clinical trial isn’t your drug, your depot, or your comparator—but the packaging decisions your team made long before the first patient was enrolled? Clinical packaging and labeling quietly consume more budget than most teams realize. The real cost drivers aren’t materials—they’re changeovers, artwork cycles, batch sizes, and […]
What if your next “perfect forecast” is actually your biggest blind spot? After more than two decades in pharmaceutical supply chains, I’ve seen one thing over and over — our collective obsession with precision. We chase the perfect model, the richest dataset, the ultimate algorithm… all hoping we’ll finally predict the future. But the truth? […]
What if the biggest risk to your First-Patient-In (FPI) date isn’t the recruitment site, but the kit design? In my 25+ years in pharmaceutical supply chain, I’ve watched many Clinical Trial Managers (CTMs) navigate the grueling path of protocol design and site selection, only to be blindsided by “the box.” While your focus is rightfully […]
If your clinical supply process is inconsistent, undocumented, or dependent on heroics, what exactly do you expect AI to optimize? There’s a growing belief that layering AI on top of operational chaos will magically create efficiency. But in clinical supply, where patient safety, expiry management, and global coordination hinge on precision, AI doesn’t fix […]
What if the biggest risk in your clinical supply chain isn’t forecasting, recruitment volatility, or vendor performance — but the silent erosion of data integrity every time information changes hands? We talk endlessly about systems, platforms, and digital transformation. Yet the real cracks often appear in the mundane moments: a spreadsheet emailed instead of uploaded, […]
The clinical supply chain has evolved from an operational function into a strategic enabler of trial readiness, regulatory success, and patient impact. As therapies advance and global trials expand, leadership—not management—defines the difference between execution and sustained excellence. This article highlights the leadership capabilities that elevate performance across communication, team development, change management, executive reporting, […]
December 30, 2025 Clinical supply chain leaders are entering 2026 with a new mandate: control costs without compromising flexibility, quality, or patient access. The pressure is real—and the organizations that get this right will accelerate development while everyone else fights fires. Here’s what’s driving the urgency: 🔹 Rising manufacturing & packaging costs Energy, […]
Clinical Supply Chains Are Entering Their “AI‑Native” Era — And 2026 Is the Breakout Year For decades, clinical supply has been treated as a back‑office function. In 2026, it’s becoming a strategic engine — one that accelerates development timelines, reduces cost, and expands global patient access. The catalyst? AI is no longer an experiment. It’s the new […]
https://www.linkedin.com/in/jgoberlander/?lipi=urn%3Ali%3Apage%3Ad_flagship3_pulse_read%3B6xTGMp88S8yrUkVanKmQOw%3D%3D Joseph G. Oberlander, Ph.D., PMP Program Manager ♦ Neuroscientist ♦ Author Clinical trials are the backbone of medical innovation, but their supply chains have traditionally been complex, fragmented, and vulnerable to disruption. From ensuring investigational drugs reach patients on time to managing global logistics, the stakes are high. Artificial Intelligence (AI) is now emerging […]
As 2025 closes, several December analyses across healthcare and supply chain publications point to the same conclusion: clinical supply chains are entering 2026 with higher volatility, tighter capacity, and increasing regulatory scrutiny — but also unprecedented opportunities for digital acceleration. A few patterns stand out: 1. Non‑labor cost pressure is now a structural reality, not […]
